Moreover, a pooled analysis of German neoadjuvant trials demonstrated significantly better OS and DFS in patients with HR-negative, HER2-low BC compared to those with HR-negative, HER2 0 disease, with survival differences observed exclusively in HR-negative tumors that failed to achieve pCR following NAC [10]. This evidence concerns the gene ERBB2 and breast cancer.